DOI: https://doi.org/10.22141/2224-1507.9.1.2019.163058

Recent recommendations on psoriatic arthritis treatment in accordance with 2018 American College of Rheumatology and National Psoriasis Foundation guidelines

I.Yu. Golovach, Ye.D. Yehudina

Abstract


Psoriatic arthritis (PsA) is a chronic inflammatory skeletal and muscular disease associated with psoriasis, which usually manifests itself in the peripheral arthritis, dactylitis, enthesitis and/or spondylitis. Early identification and diagnosis of PsA, as well as early start of therapy is important for improving the long-term outcomes of the disease. Clinical picture of PsA is heterogeneous, and doctors often face problems while determining treatment strategies. The purpose of our review was to discuss and interpret 2018 American College of Rheumatologists (ACR) and National Psoriasis Foundation (NPF) guidelines for active PSA treatment in adults using pharmacological and non-pharmacological methods. These recommendations may help both clinicians and patients to make their best decisions about disease management. The presence or absence of comorbid conditions such as inflammatory bowel disease, uveitis, diabetes or serious infections, as well as knowledge of medical history are factors enabling choice of an optimal therapy for a particular patient at a given time using a customized treatment approach. ACR/NPF guidelines for active PsA treatment recommend tumor necrosis factor inhibitors rather than small molecule oral drugs as a first line therapy, precisely because these biological agents prevent progression of the disease and joint damage. Early and aggressive therapy is emphasized in patients with a newly diagnosed PsA.


Keywords


psoriatic arthritis; psoriasis; activity of the process; recommendations; treatment; management; tumor necrosis factor inhibitors; interleukin-17 inhibitors; interleukin-12/23 inhibitors; methotrexate; treat-to-target

References


Menter A. Psoriasis and psoriatic arthritis overview. Am J Manag Care. 2016 Jun;22(8 Suppl):s216-24.

Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):545-68. doi: 10.1016/j.rdc.2015.07.001.

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017 Mar 9;376(10):957-970. doi: 10.1056/NEJMra1505557.

Adams R, Walsh C, Veale D, Bresnihan B, FitzGerald O, Barry M. Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis. Pharmacoeconomics 2010;28(6):477-87. doi: 10.2165/11533010-000000000-00000.

Singh JA, Strand V. Health care utilization in patients with spondyloarthropathies. Rheumatology (Oxford). 2009 Mar;48(3):272-6. doi: 10.1093/rheumatology/ken472.

Cresswell L, Chandran V, Farewell VT, Gladman DD. Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. Ann Rheum Dis 2011;70(2):305–8. doi: 10.1136/ard.2010.135087.

Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-73.doi: 10.1002/art.21972.

Yaremenko OB, Fedkov DL, Yaremenko KM. The possibilities of objectification of inflammatory-destructive process in psoriatic arthritis. Ukrainian journal of rheumatology. 2011;46(4):1-7. (in Ukrainian).

Felson DT, Andersen JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727-35.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-71. doi: 10.1002/art.39573.

Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337.

Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog Treat. 2004 Jan;15(1):27-9. doi: 10.1080/09541440042000269.

Gladman DD. Early psoriatic arthritis. Rheum Dis Clin North Am. 2012 May;38(2):373-86. doi: 10.1016/j.rdc.2012.05.005.

Yaremenko OB, Fedkov DL. Efficacy and tolerance of psoriatic arthritis basic therapy using leflunomide. Ukrainian journal of rheumatology. 2011;(45):21-26.

Baranauskaite A, Raffayová H, Kungurov NV, et al. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study. Ann Rheum Dis. 2012 Apr;71(4):541-8. doi: 10.1136/ard.2011.152223.

Heiberg MS, Kaufmann C, Rødevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. Ann Rheum Dis. 2007 Aug;66(8):1038-42. doi: 10.1136/ard.2006.064808.

Eder L, Thavaneswaran A, Chandran V, Gladman DD. Tumour necrosis factor α

blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis. 2014 Jun;73(6):1007-11. doi: 10.1136/annrheumdis-2012-202959.

Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol. 2011 Nov;165(5):1109-17. doi: 10.1111/j.1365-2133.2011.10615.x.

Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008 Mar;158(3):558-66. doi: 10.1111/j.1365-2133.2007.08315.x.

Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012;51(8):1368-77. doi: 10.1093/rheumatology/kes001.

Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995 May;22(5):894-8.

Combe B, Goupille P, Kuntz JL, Tebib J, Liote F, Bregeon C. Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study. Br J Rheumatol. 1996 Jul;35(7):664-8.

Farr M, Kitas GD, Waterhouse L, Jubb R, Felix-Davies D, Bacon PA. Sulphasalazine in psoriatic arthritis: a double-blind placebo- controlled study. Br J Rheumatol. 1990 Feb;29(1):46-9.

Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005 Oct;52(10):3279-89.

Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis. 2007 Feb;66(2):163-8. doi: 10.1136/ard.2006.057901.

Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264-72. doi: 10.1002/art.20335.

Mease PJ, Woolley JM, Singh A, Tsuji W, Dunn M, Chiou CF. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. J Rheumatol 2010;37(6):1221-7. doi: 10.3899/jrheum.091093.

Mease PJ, Goffe BS, Metz J, Vander Stoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul;356(9227):385-90. doi: 10.1016/S0140-6736(00)02530-7.

Singh J A, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726.

Lubrano E, Scriffignano S, Perrotta FM. Abatacept for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2018 Nov;14(11):899-905. doi: 10.1080/1744666X.2018.1527218.

Lubrano E, Perrotta FM. The role of ІЛ-17 in the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2017;13(8):815-821. doi: 10.1080/1744666X.2017.1327354.

Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377(16):1525-1536. doi: 10.1056/NEJMoa1615977.

Metyas S, Tomassian C, Messiah R, Gettas T, Chen C, Quismorio A. Combination Therapy of Apremilast and Biologic Agent as a Safe Option of Psoriatic Arthritis and Psoriasis. Curr Rheumatol Rev. 2018. doi: 10.2174/1573397115666181130094455.

Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W, Wojtkiewicz M, Wojtkiewicz J. Effect of Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Patients with Nail Psoriasis. J Clin Med. 2018;7(12). pii: E546. doi: 10.3390/jcm7120546.

D’Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017 Mar 2;9:21-28. doi: 10.2147/OARRR.S56073.

Yun H, Xie F, Delzell E, et al. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. Arthritis Rheumatol. 2016 Jan;68(1):56-66. doi: 10.1002/art.39399.

Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719-730. doi: 10.1080/1744666X.2018.1512404.

Elmamoun M, Chandran V. Role of Methotrexate in the Management of Psoriatic Arthritis. Drugs. 2018;78(6):611-619. doi: 10.1007/s40265-018-0898-2.

Favalli EG, Selmi C, Becciolini A, et al. Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. Arthritis Care Res (Hoboken). 2017 Jun;69(6):867-874. doi: 10.1002/acr.23090.

Ritchlin CT, Krueger JG. New Therapies for Psoriasis and Psoriatic Arthritis. Curr Opin Rheumatol. 2016;28(3):204-210. doi: 10.1097/BOR.0000000000000274.

Boutet MA, Nerviani A, Afflitto GG, Pitzalis C. Role of the ІЛ-23/ІЛ-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints. Int J Mol Sci. 2018 Feb 9;19(2). pii: E530. doi: 10.3390/ijms19020530.

Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting ІЛ-17 in psoriatic arthritis. Eur J Rheumatol. 2017 Dec;4(4):272-277. doi: 10.5152/eurjrheum.2017.17037.

Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-ІЛ-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73(6):990-9. doi: 10.1136/annrheumdis-2013-204655.

Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016;68(2):282-98. doi: 10.1002/art.39298.

Janssen Research Development, LLC, sponsor. An efficacy and safety study of ustekinumab in participants with active nonradiographic axial spondyloarthritis. ClinicalTrials.gov Identifier: NCT02407223. 2017. Available from: https://clinicaltrials.gov/ct2/show/NCT02407223. Accessed: October 25, 2017.

Janssen Research Development, LLC, sponsor. A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis. ClinicalTrials.gov Identifier: NCT02437162. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02437162. Accessed: October 29, 2018.

Janssen Research & Development, LLC, sponsor. A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis. ClinicalTrials.gov identifier: NCT02438787. 2018. Available from: https://clinicaltrials.gov/ct2/show/NCT02438787. Accessed: October 10, 2018.

Sakkas LI, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013 Dec;43(3):325-34. doi: 10.1016/j.semarthrit.2013.04.005.

Cohen BL, Sachar DB. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017 Jun 19;357:j2505. doi: 10.1136/bmj.j2505.

Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 Dec;61(12):1693-700. doi: 10.1136/gutjnl-2011-301668.

Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol 2014;171(1):17-29. doi: 10.1111/bjd.12941.

Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009;51(4):778ß86. doi: 10.1016/j.jhep.2009.06.008.

Golovach IYu. The Role of Smoking in the Development of Psoriatic Arthritis and Psoriasis. Bolʹ, sustavy, pozvonočnik. 2016;(23):42-48. doi: 10.22141/2224-1507.3.23.2016.85006. (in Russian).

Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. Change in mental health after smoking cessation: systematic review and meta-analysis. BMJ. 2014 Feb 13;348:g1151. doi: 10.1136/bmj.g1151.

Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69(1):48-53. doi: 10.1136/ard.2008.102053.

Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016;75(5):811-8. doi: 10.1136/annrheumdis-2015-207507.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta-Felquer ML, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-71. doi: 10.1002/art.39573.






Copyright (c) 2019 PAIN. JOINTS. SPINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта